Table 1 The basic characteristics of the included study
Source | Year | Study year | Study design | No. of patients | No. of myasthenic crisis cases | Age at thymectomy (mean) Age, years | Gender Male/women | Study region | Non-thymomatous/thymoma | Significant risk factors | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Kato | 2019 | 2000–2015 | retrospective cohort study | 90 | 14 | median (range) 51.5 (41.3–64.0) | 41/46 | Japan | 33/57 | (15) | 8 |
Xue | 2017 | 2005–2014 | case-control studies | 127 | 13 | NA | 68/59 | china | 127 | (3),(10) | 8 |
Zou | 2016 | 2007.06–2013.12 | retrospective cohort study | 541 | 67 | 26.4 ± 11.7/27.06 ± 13.5 | 256/285 | china | NA | (1),(4),(6),(16) | 6 |
Ando | 2015 | 2000.01–2013.12 | case-control studies | 55 | 10 | median (range) 55 (13–79) | 25/30 | Japan | 30/25 | (1),(17) | 7 |
Lee | 2015 | 2007.10–2012.03 | case-control studies | 146 | 10 | T/C 25.0 (15.5–48.0)/35.0 (27.0–46.0) | NA | Korea | 105/41 | (12),(18) | 8 |
Li | 2018 | 2000.01–2013.03 | case-control studies | 176 | 51 | 46.6 ± 11.7 | 90/83 | China | 0/173 | (2),(19) | 9 |
Yu | 2014 | 1997.03–2012.03 | retrospective cohort study | 178 | 58 | 38.4 ± 13.2 | 95/83 | China | 69/109 | (1),(2),(8) | 8 |
Choi | 2014 | 1996.01–2009.12 | retrospective cohort study | 49 | 12 | 50.3 ± 12.4 | 23/25 | Korea | 0/49 | (12) | 6 |
Leuzzi | 2014 | 1995.01–2011.12 | case-control studies | 177 | 22 | 45.8 ± 16.8 | 107/70 | Italy | 53/124 | (1),(3),(4),(14) | 9 |
Nam | 2011 | 1997.01–2007.12 | retrospective cohort study | 68 | 20 | age at onset 43.6 ± 13.9 | NA | Japan | 28/38 | (1) | 9 |
Chu | 2011 | 1990–2009 | case-control studies | 243 | 44 | 31.5 ± 15.7 | 124/119 | China | 175/68 | (3),(5),(13) | 5 |
Liu | 2006 | 1990.01–2006.01 | case-control studies | 176 | 36 | 31 ± 14 | 74/102 | China | 122/54 | (1),(2),(6),(24) | 9 |
Li | 2016 | 1970.05–2011.05 | case-control studies | 306 | 49 | 31.54 ± 16.37 | 155/151 | China | NA | (1),(2),(5) | 8 |
Qian | 2016 | 2002.02–2015.06 | case-control studies | 86 | 16 | median (range)47 (25–71) | 37/49 | China | 40/46 | (1),(2),(3) | 8 |
Li | 2017 | 2008.01 ~ 2015.01 | case-control studies | 63 | 12 | median (range)37 (10–76) | 25/38 | China | 41/22 | (3),(8),(9),(10) | 7 |
Liu | 2014 | 2011.01–2014.02 | case-control studies | 102 | 42 | T/C 46.7 ± 10.11/39.6 ± 6.41 | 45/57 | China | 36/66 | (3),(5),(11),(12),(20) | 6 |
Niu | 2013 | 2002.07–2012.07 | case-control studies | 134 | 28 | age at onset 35 (1–82) | 66/68 | China | 69/65 | (3) | 6 |
Ma | 2011 | 1995.07–2009.12 | case-control studies | 84 | 24 | median (range)42.67 (16—68) | 35/49 | China | 21/63 | (1),(3),(8),(11) | 6 |
Zhang | 2015 | 2008.06–2014.06 | case-control studies | 58 | 15 | T/C 60.60 ± 6.20/60.7 ± 6.3 | 26/32 | China | 0/58 | (3),(11),(21) | 6 |
Wang | 2006 | NA | case-control studies | 126 | 13 | median (range)38 (9–62) | 54/72 | China | 56/70 | (1),(3),(7),(22) | 5 |
Chen | 2007 | 2002.07–2005.12 | case-control studies | 101 | 29 | 33.2 ± 14.67 | 43/58 | China | 33/68 | (1),(3),(4),(13),(23) | 8 |
Ge | 2019 | 2008.01–2018.01 | retrospective cohort study | 47 | 14 | 40.1 ± 16.7 | 22/25 | China | 24/23 | (11),(13) | 6 |
Li | 2014 | 2008.01–2013.06 | case-control studies | 198 | 32 | NA | NA | China | 135/63 | (1),(3),(5),(6) | 5 |
Kanai | 2017 | 2002.01–2014.12 | case-control studies | 275 | 17 | T/C:45.8 ± 16.1/49.2 ± 15.5 | 106/169 | Japan | 145/130 | (2),(12),(14) | 9 |
Watanabe | 2004 | 1985.01–2002.12 | retrospective cohort study | 122 | 44 | 44 ± 17 | 30/92 | Japan | 93/29 | (2),(7),(9) | 6 |